Skip to main content

Table 4 Risks of death and hospitalisations

From: Clinical effects, cardiovascular and renal outcomes associated with rapid-acting insulin analogs among individuals with type 2 diabetes: a nation-wide observational cohort study

Event Aspart vs lispro Glulisine vs lispro Glulisine vs aspart
Total Mortality 1.23 [0.98, 1.53] 0.65 [0.41, 1.53] 0.53 [0.35, 0.8]*
CHD 0.96 [0.82, 1.12] 1.03 [0.79, 1.36] 1.08 [0.85, 1.35]
Fatal CHD 1.17 [0.79, 1.74] 1.04 [0.50, 2.16] 0.89 [0.47, 1.67]
CVD 0.95 [0.82, 1.09] 1.03 [0.80, 1.31] 1.08 [0.88, 1.33]
Fatal CVD 1.15 [0.80, 1.66] 0.88 [0.44, 1.78] 0.77 [0.41, 1.42]
Stroke 0.94 [0.67, 1.34] 0.33 [0.16, 0.66]* 0.34 [0.18, 0.65]*
Heart Failure 1.00 [0.82, 1.23] 0.76 [0.50, 1.13] 0.75 [0.53, 1.08]
Kidney Failure 0.88 [0.68, 1.13] 0.71 [0.42, 1.20] 0.81 [0.50, 1.30]
Hypoglycaemia 1.42 [0.83, 2.44] 1.30 [0.55, 3.10] 0.92 [0.45, 1.85]
Hyperglycaemia 1.97 [1.01, 3.85]* 1.88 [0.66, 5.33] 0.96 [0.42, 2.18]
  1. Weighted Cox proportional hazards analysis. Estimated hazard ratios with 95% confidence intervals. * p-value <0.05